Drug delivery apparatus and method preventing local and systemic toxicity

• US 5,024,657 A
• Filed: 05/04/1990
• Issued: 06/18/1991
• Est. Priority Date: 12/03/1984
• Status: Expired due to Term

• Current Assignee: Baxter International Inc.
• Original Assignee: Baxter International Inc.
• Inventors: Pearson, Steve, Kopp, Clinton V., Wright, Jeremy C., Needham, Thomas E., Chilamkurti, Rao
• Primary Examiner(s): Hill, Jr., Robert J.
• Application Number:
  US07/518,272
• Time in Patent Office: 410 Days
• Field of Search: 604/80-85, 604/56, 604/251, 604/252, 604/416
• US Class Current: 604/85
• CPC Class Codes: A61M 5/1409 in series, e.g. first substance passing through container holding second substance, e.g. reconstitution systems needle sets A61M5/162

Abstract

An apparatus is provided for the safe, passive reconstruction of a drug or other beneficial agent, without requiring manual reconstitution steps. The apparatus includes a housing, preferably having a receptacle "in-line" in an administration set and forming part of an intravenous delivery system, and a cartridge adapted for receiving a beneficial agent or beneficial agent and carrier. The cartridge is plugged into the receptacle to initiate reconstitution of the agent. The apparatus creates first and second delivery modes, in which the delivery rate of the agent to a patient is independent from and dependent upon, respectively, the fluid flow rate through the intravenous delivery system.

Claims

1. Apparatus for the safe delivery of a beneficial agent to a patient, comprising:

(a) means defining a chamber adapted for receiving a beneficial agent, said chamber having a fluid pathway therethrough, said chamber-defining means including an inlet and an outlet defining part of said fluid pathway; and

(b) means for controlling the rate of delivery of the beneficial agent out of said outlet and into a patient, said control means being capable of producing first and second delivery modes for the beneficial agent when the beneficial agent is being delivered to a patient, such that in said first delivery mode the fluid flow rate through said chamber is high enough that the rate of delivery of the beneficial agent is substantially independent of the fluid flow rate through said chamber, wherein the rate of delivery of the beneficial agent, when the agent delivery rate is independent of fluid flow rate, is at a rate high enough to create, but for said second delivery mode, a locally toxic concentration of beneficial agent in the fluid delivered to the patient, and such that in said second delivery mode, the fluid flow rate through said chamber is slow enough that the rate of delivery of the beneficial agent is at least partially dependent upon the fluid flow rate through said chamber;

(c) said control means causing said second delivery mode to include fluid flow rates high enough to prevent a locally toxic concentration of beneficial agent in the fluid delivered to the patient, said control means furthermore causing said first delivery mode to include fluid flow rates low enough to prevent a systemically toxic concentration of beneficial agent in the bloodstream of the patient.

2. The apparatus in accordance with claim 1, wherein said apparatus is adapted for placement in a fluid delivery system including a fluid source and a fluid conduit, wherein said inlet and said outlet of said chamber-defining means are adapted for connection to the fluid conduit, such that said fluid pathway forms aprt of the fluid conduit.

3. The apparatus in accordance with claims 1 or 2, further comprising the beneficial agent within said chamber.

4. The apparatus in accordance with claim 3, further comprising a carrier for said beneficial agent, within said chamber.

5. The apparatus in accordance with claim 4, in which said control means comprises the local velocity profile of fluid passing over the beneficial agent.

6. The apparatus in accordance with claim 4, in which said control means comprises the thickness of the diffusional boundary layer of the fluid passing over the beneficial agent.

7. The apparatus in accordance with claim 4 wherein said control means comprises the percentage of void volume of said beneficial agent.

8. The apparatus in accordance with claim 4 wherein said control means comprises the rate of dissolution of said beneficial agent.

9. The apparatus in accordance with claim 4 wherein said beneficial agent comprises separable particles and wherein said control means comprises the particle size of said beneficial agent.

10. The apparatus in accordance with claim 4 wherein said control means comprises the amount of surface area of said beneficial agent in contact with fluid flowing through said fluid pathway.

11. The apparatus in accordance with claim 4 in which said control means comprises the shape of said beneficial agent within said chamber.

12. The apparatus in accordance with claim 4, in which said control means comprises the weight ratio of said beneficial agent to said carrier.

13. The apparatus in accordance with claim 4, in which said control means comprises the percentage of void volume of said carrier with said beneficial agent therein.

14. The apparatus in accordance with claim 4, in which said control means comprises the percentage of void volume of said carrier as measured without said beneficial agent therein.

15. The apparatus in accordance with claim 4, in which said carrier is dissolvable and in which said control means comprises the rate of dissolution of said carrier.

16. The apparatus in accordance with claim 4, in which said carrier includes separable particles and in which said control means comprises the size of said carrier particles.

17. The apparatus in accordance with claim 4, wherein said control means comprises the amount of surface area of said carrier, with said beneficial agent therein, in contact with fluid flowing through said fluid pathway.

18. The apparatus in accordance with claim 4, in which said control means comprises the shape of said carrier, with said beneficial agent therein.

19. The apparatus as in claim 4, wherein said carrier is mannitol.

20. The apparatus as in claim 4, wherein said carrier comprises a porous polypropylene tablet.

21. The apparatus as in claim 4, wherein said carrier comprises polypropylene beads.

22. The apparatus in accordance with claim 4, in which said control means comprises the thickness of the diffusional boundary layer of the fluid passing over said carrier.

23. The apparatus in accordance with claim 4, in which said control means comprises the thickness of the diffusional boundary layer of the fluid passing over said agent and said carrier.

24. The apparatus in accordance with claim 1, in which said carrier does not dissolve.

25. The apparatus in accordance with claim 1, in which said control means provides for a first delivery mode enabling a therapeutic dose of the beneficial agent to be delivered in a time period not greater than the maximum therapeutically acceptable time period.

26. The apparatus in accordance with claim 2, in which said first delivery mode enables a therapeutic dose of the beneficial agent to be delivered in a time period of approximately thirty minutes.

27. The apparatus in accordance with claim 1, in which said control means comprises the cross-sectional area of said fluid pathway.

28. The apparatus in accordance with claim 1, in which said control means compriss a plurality of non-series connecting fluid pathway segments forming said fluid pathway, in which at least one fluid pathway segment is exclusive of flow-path communication with the beneficial agent.

29. The apparatus in accordance with claim 1, further wherein said chamber-defining means comprises housing means.

30. The apparatus in accordance with claim 29, further wherein said apparatus is adapted for placement in an intravenous delivery system including a fluid source and a fluid conduit.

31. The apparatus in accordance with claim 29, further comprising a fluid conduit having proximal anddistal ends, said proximal end being adapted for communicating with a fluid source, said distal end being adapted for communicating with the intravenous system of the patient, said housing means being interposed in and forming part of said fluid conduit, such that said chamber fluid pathway, including said inlet and said outlet, are in fluid communication with said fluid conduit.

32. The apparatus in accordance with claim 1 in which said control means comprises the volume of said chamber.

33. The apparatus in accordance with claim 1, in which said control means comprises the configuration of the flow path through said chamber.

34. The apparatus as in claim 1, wherein said control means causes said first and second delivery modes to be separated by a fluid flow rate transition region wherein the degree of dependence of the rate of beneficial agent delivery upon the fluid flow rate changes significantly.

35. The apparatus as in claim 34, wherein the fluid flow rate transition region is between fluid flow rates of about thirty and sixty milliliters per hour.

36. The apparatus as in claim 1, wherein said apparatus operates in the first delivery mode at fluid flow rates at or above about sixty milliliters per hour.

37. A method for mixing a beneficial agent with a fluid and safely delivering the agent to a patient, the steps comprising:

(a) providing an intravenous delivery system including a fluid source and a fluid conduit connected to the fluid source for delivering fluid in the source to the patient;

(b) providing a housing within the fluid conduit, the housing defining a chamber with the beneficial agent therein, the chamber having a fluid pathway therethrough in fluid communication with the fluid conduit both upstream and downstream of the housing; and

(c) automatically controlling the rate of delivery of the beneficial agent out of the housing outlet and into a patient, said control step including

(i) providing capability for producing a first delivery mode to a patient in which the rate of delivery of the beneficial agent is substantially independent of the fluid flow rate through the chamber, wherein the rate of the delivery of the beneficial agent, when the agent delivery rate is independent of fluid flow rate, is at a rate high enough to create, but for a second delivery mode, a locally toxic concentration of beneficial agent in the fluid delivered to the patient,

(ii) providing capability for producing a second delivery mode to a patient at fluid flow rates lower than the first delivery mode, in which the rate of delivery of the beneficial agent is at least partially dependent upon the fluid flow rate through the chamber and

(iii) separating the first and second delivery modes at a fluid flow rate transition region high enough to prevent a toxic concentration of beneficial agent in the fluid delivered to the patient.

38. The method as in claim 37, wherein said control step further comprises producing a first delivery mode such that the rate of delivery of the beneficial agent is low enough to prevent a toxic concentration of beneficial agent in the bloodstream of the patient.

39. Apparatus for the safe delivery of a beneficial agent to a patient, comprising:

(a) means defining a chamber adapted for receiving a beneficial agent, said chamber having a fluid pathway therethrough, said chamber-defining means including an inlet and an outlet defining part of said fluid pathway; and

(b) means for controlling the rate of delivery of the beneficial agent out of said outlet and into a patient, said control means being capable of producing first and second delivery modes for the beneficial agent when the beneficial agent is being delivered to a patient,

(i) such that in said first delivery mode the fluid flow rate through said chamber is high enough that the rate of delivery of the beneficial agent is substantially independent of the fluid flow rate through said chamber such that said apparatus, when in said first delivery mode, enables a therapeutic dose of the beneficial agent to be delivered to the patient in a time period of approximately thirty minutes, and

(ii) such that in said second delivery mode, the fluid flow rate through said chamber is slow enough that the rate of delivery of the beneficial agent is at least partially dependent upon the fluid flow rate through said chamber;

(c) said control means causing said second delivery mode to include fluid flow rates high enough to prevent a locally toxic concentration of beneficial agent in the fluid delivered to the patient, said control means furthermore causing said first delivery mode to include fluid flow rates low enough to prevent a systemically toxic concentration of beneficial agent in the bloodstream of the patient.

40. Apparatus for the safe delivery of a beneficial agent to a patient, comprising:

(a) means defining a chamber adapted for receiving a beneficial agent, said chamber having a fluid pathway therethrough, said chamber-defining means including an inlet and an outlet defining part of said fluid pathway; and

(b) means for controlling the rate of delivery of the beneficial agent out of said outlet and into a patient, said control means producing first and second delivery modes for the beneficial agent when the beneficial agent is being delivered to a patient, such that in said first delivery mode the fluid flow rate through said chamber is high enough that the rate of delivery of the beneficial agent is substantially independent of the fluid flow rate through said chamber, wherein the rate of delivery of the beneficial agent, when the agent delivery rate is independent of fluid flow rate, is at a rate high enough to create, but for said second delivery mode, a locally toxic concentration of beneficial agent in the fluid delivered to the patient, and such that in said second delivery mode, the fluid flow rate through said chamber is slow enough that the rate of delivery of the beneficial agent is at least partially dependent upon the fluid flow rate through said chamber;

(c) said control means causing said second delivery mode to include fluid flow rates high enough to prevent a locally toxic concentration of beneficial agent in the fluid delivered to the patient, said control means furthermore causing said first delivery mode to include fluid flow rates low enough to prevent a systemically toxic concentration of beneficial agent in the bloodstream of the patient.

41. A method for mixing a beneficial agent with a fluid and safely delivering the agent to a patient, the steps comprising:

(a) providing an intravenous delivery system including a fluid source and a fluid conduit connected to the fluid source for delivering fluid in the source to the patient;

(b) providing a housing within the fluid conduit, the housing defining a chamber with the beneficial agent therein, the chamber having a fluid pathway therethrough in fluid communication with the fluid conduit both upstream and downstream of the housing; and

(c) automatically controlling the rate of delivery of the beneficial agent out of the housing outlet and into a patient, said control step including

(i) producing a first delivery mode to a patient in which the rate of delivery of the beneficial agent is substantially independent of the fluid flow rate through the chamber, wherein the rate of the delivery of the beneficial agent, when the agent delivery rate is independent of fluid flow rate, is at a rate high enough to create, but for a second delivery mode, a locally toxic concentration of beneficial agent in the fluid delivered to the patient,

(ii) producing a second delivery mode to a patient at fluid flow rates lower than the first delivery mode, in which the rate of delivery of the beneficial agent is at least partially dependent upon the fluid flow rate through the chamber and

(iii) separating the first and secon delivery modes at a fluid flow rate trnasition region high enough to prevent a toxic concentration of beneficial agent in the fluid delivered to the patient.

42. Apparatus for the safe delivery of a beneficial agent to a patient, comprising:

(a) means defining a chamber adapted for receiving a beneficial agent, said chamber having a fluid pathway therethrough, said chamber-defining means including an inlet and an outlet defining part of said fluid pathway; and

(b) means for controlling the rate of delivery of the beneficial agent out of said outlet and into a patient, said control means producing first and second delivery modes for the beneficial agent when the beneficial agent is being delivered to a patient,

(i) such that in said first delivery mode the fluid flow rate through said chamber is high enough that the rate of delivery of the beneficial agent is substantially independent of the fluid flow rate through said chamber such that said apparatus, when in said first delivery mode, enables a therapeutic dose of the beneficial agent to be delivered to the patient in a time period of approximately thirty minutes, and

(ii) such that in said second delivery mode, the fluid flow rate through said chamber is slow enough that the rate of delivery of the beneficial agent is at least partially dependent upon the fluid flow rate through said chamber;

(c) said control means causing said second delivery mode to include fluid flow rates high enough to prevent a locally toxic concentration of beneficial agent in the fluid delivered to the patient, said control means furthermore causing said first delivery mode to include fluid flow rates low enough to prevent a systemically toxic concentration of beneficial agent in the bloodstream of the patient.